CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
A	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Castration-resistant Prostate Carcinoma	Olaparib	de Bono et al., 2020
D	FGFR3	R248C	Functional	Supports	Gain of Function			Naski et al., 1996
D	TP53	P250L	Functional	Supports	Gain of Function			Xu et al., 2011
A	KRAS	G12C	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Sotorasib	Skoulidis et al., 2021
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Encorafenib,Cetuximab	Kopetz et al., 2019
B	ERBB2	Exon 20 Insertion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trastuzumab Deruxtecan	Li et al., 2022
B	BCOR	ITD	Diagnostic	Supports	Positive	Kidney Clear Cell Sarcoma		Roy et al., 2015
A	IDH1	R132	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Ivosidenib	Abou-Alfa et al., 2020
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Brigatinib	Camidge et al., 2020
A	v::ROS1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Entrectinib	Drilon et al., 2020
A	v::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Solid Tumor	Entrectinib	Doebele et al., 2020
A	v::NTRK3	Fusion	Predictive	Supports	Sensitivity/Response	Solid Tumor	Entrectinib	Doebele et al., 2020
A	BRCA1	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Rucaparib	Oza et al., 2017
A	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Rucaparib	Oza et al., 2017
A	BRCA1	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Rucaparib	Oza et al., 2017
A	BRCA2	Mutation	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Rucaparib	Oza et al., 2017
A	BRCA1	Loss-of-function	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Olaparib	Tutt et al., 2021
A	BRCA2	Loss-of-function	Predictive	Supports	Sensitivity/Response	Her2-receptor Negative Breast Cancer	Olaparib	Tutt et al., 2021
A	BRCA1	Loss-of-function	Predictive	Supports	Sensitivity/Response	Triple-receptor Negative Breast Cancer	Olaparib	Tutt et al., 2021
A	BRCA2	Loss-of-function	Predictive	Supports	Sensitivity/Response	Triple-receptor Negative Breast Cancer	Olaparib	Tutt et al., 2021
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Wu et al., 2020
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Dacomitinib	Wu et al., 2017
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Ramucirumab	Nakagawa et al., 2019
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Margetuximab	Rugo et al., 2021
A	IDH1	R132C OR IDH1 R132H OR IDH1 R132L OR IDH1 R132G OR IDH1 R132S	Predictive	Supports	Sensitivity/Response	Low Grade Glioma	Vorasidenib	Mellinghoff et al., 2023
A	IDH2	R172K OR IDH2 R172G OR IDH2 R172W	Predictive	Supports	Sensitivity/Response	Low Grade Glioma	Vorasidenib	Mellinghoff et al., 2023
B	IGH::CRLF2	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like		Roberts et al., 2014
A	TPM3::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Solid Tumor	Larotrectinib Regimen	Drilon et al., 2018
A	TCF3::PBX1	Fusion	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With TCF3-PBX1		Alaggio et al., 2022
B	CBFB::MYH11	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With Inv(16)(p13.1q22) Or T(16;16)(p13.1;q22)		Marcucci et al., 2005
B	CBFB::MYH11	Fusion	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With Inv(16)(p13.1q22) Or T(16;16)(p13.1;q22)		Schlenk et al., 2004
A	RUNX1::RUNX1T1	Fusion	Prognostic	Supports	Better Outcome	Acute Myeloid Leukemia With T(8;21); (q22; Q22.1)		Grimwade et al., 1998
A	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Alectinib	Wu et al., 2024
A	ERBB2	Overexpression	Predictive	Supports	Sensitivity/Response	Solid Tumor	Trastuzumab Deruxtecan	Meric-Bernstam et al., 2024
A	EGFR	L858R OR EGFR Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib,Chemotherapy	Planchard et al., 2023
A	BRAF	V600E OR KIAA1549::BRAF Fusion	Predictive	Supports	Sensitivity/Response	Childhood Low-grade Glioma	Tovorafenib	Kilburn et al., 2024
A	BRAF	V600 OR v::BRAF Fusion	Predictive	Supports	Sensitivity/Response	Childhood Low-grade Glioma	Tovorafenib	Kilburn et al., 2024
A	C19MC	Amplification	Diagnostic	Supports	Positive	Embryonal Tumor With Multilayered Rosettes, C19MC-altered		Li et al., 2009
A	C19MC	TTYH1::C19MC fusion	Diagnostic	Supports	Positive	Embryonal Tumor With Multilayered Rosettes		Kleinman et al., 2014
A	C19MC	v::C19MC fusion	Diagnostic	Supports	Positive	Embryonal Tumor With Multilayered Rosettes		Lambo et al., 2019
B	FGFR1	Amplification	Prognostic	Supports	Poor Outcome	Breast Cancer		O'Leary et al., 2021
B	FGFR1	Amplification	Prognostic	Supports	Poor Outcome	Breast Cancer		Mouron et al., 2021
D	FGFR1	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Fulvestrant,Rogaratinib,Palbociclib	Mouron et al., 2021
B	JAK2	V617F	Diagnostic	Supports	Negative	Lymphoid Leukemia		Levine et al., 2005
B	JAK2	V617F	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		Levine et al., 2005
B	JAK2	V617F	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		Levine et al., 2005
B	JAK2	V617F	Diagnostic	Supports	Positive	Bone Marrow Cancer		Kilpivaara et al., 2009
B	DNMT3A	R882	Predictive	Does Not Support	Resistance	Acute Myeloid Leukemia	Daunorubicin	LaRochelle et al., 2011
B	NRAS	Q61	Predictive	Supports	Resistance	Melanoma	Vemurafenib	Trunzer et al., 2013
B	PDGFRA	D842V	Predictive	Supports	Resistance	Gastrointestinal Stromal Tumor	Imatinib	Corless et al., 2005

Page 4 of 96

Previous Next